Biometrics for Clinical Trials

Build Critical Decisions
on Solid Evidence

Our clinical trial biometrics do more than support execution and final outcomes. They de-risk your clinical development with smarter planning, so you can move at the speed of science.

We partner early on study design, estimands, and analysis strategy, and support confident regulatory interactions. Backed by statistical programming, data management, and analytics, we reduce risk, accelerate timelines, and deliver credible, submission-ready results.

Strategy First, Stats Second

We’re not a biometrics vendor; we’re a strategic partner that anticipates feedback, optimizes protocols, and delivers high-quality, submission-ready results.

We make regulatory biostatistics part of your program’s foundation to:

Enhance Trial Design

We drive strategy-led trial design, keeping regulatory readiness in mind across endpoints, estimands, assumptions, and adaptive options. Through early effective engagement, we help reduce revisions, minimize rework, and enable faster finalization with greater confidence ahead of key health authority interactions.

Accelerate Data-Driven Decisions

With streamlined data flow and near real-time visibility, you can expect timely insights for safety and efficacy oversight, supporting confident decisions, stronger governance, and reduced operational risk.

Give You Defensible Confidence

Receive CDISC-compliant outputs and aligned reporting as we support high-quality clinical study reports (CSRs) and defensible analyses, driving regulatory credibility, fewer review cycles, and confidence in conclusions.

De-Risk Development

Continuous oversight, integrated governance, and timely intervention are our secret ingredients to a low-risk trial, while our biometrics expertise helps:

Prevent Design Churn

We help sponsors lock in robust trial architecture, estimands, and sample size assumptions early, reducing late-stage protocol changes, aptly and flexibly dealing with unexpected outcomes, minimizing rework, and accelerating confident, efficient progress.

Strengthen Inference Credibility

We rigorously test assumptions, validate models, and apply sensitivity analyses to deliver robust, defensible results.

Meet Submission Timelines

By optimizing sequencing, controlling multiplicity, and aligning deliverables, we reduce downstream delays and minimize rework.

I’m driven to help sponsors protect timelines and avoid costly amendments by integrating biostatistics across functions. Early integration prevents late surprises and enables more timely, scientifically defensible decisions.

Shoeb Hasham - Executive Director, Biostats and Statistical Programming

Our Integrated Biometrics for Clinical Trials

From trial design and statistical strategy to traceable, reproducible programming, we give you an accelerated, transparent data flow, near real-time visibility, and enhanced data management, clinical operations, and medical writing integrations.

Our services include:

Regulatory biostatistics (study design, estimands, and regulatory interaction strategy)
Quantitative modeling and simulation-based decision support
Interim analysis planning, conduct, and interpretation of results
Dynamic risk monitoring strategies
In-depth interpretation of study results and value forecasting
Statistical programming
Data flow and monitoring support
CDISC-compliant standards and submission deliverables
Cross-functional integration

How Can Caidya Help Your Clinical Trial Biostatistics?

No matter what phase you’re in, our scalable biometrics protect timelines, ensure analysis readiness, and use defensible methods with expertise from:

400+ clinical analytics experts across our biometrics and data management teams
500+ biometrics projects across Phases I-III in the last 5 years

Frequently Asked Questions About Our
Biostatistics Services for Clinical Trials

When should Biostatistics and Statistical Programming be engaged in trial planning?

Ideally, at study concept and protocol design, so that estimands, endpoints, sample size, and analysis strategy are aligned from the start, reducing downstream rework and meeting critical timelines.

How do you reduce protocol amendments driven by late statistical input?

By embedding biostatistics early in design decisions and ensuring statistical feasibility is tested upfront, avoiding late-stage changes that disrupt execution and timelines.

How do you ensure analysis readiness when data cleaning/standardization is underestimated?

We support upfront analysis-ready planning, aligned standards, and coordinated data management and programming processes to create datasets that are structured correctly from the outset.

How do you support interim analyses and adaptive decision points without delaying timelines?

By pre-defining decision frameworks, aligning programming execution early, and sequencing interim deliverables to enable timely, disruption-free analyses.

How do you ensure statistical methods are robust and assumptions are justified?

We provide rigorous methodological review, explicit assumption checking, and sensitivity analyses that strengthen inference credibility and regulatory confidence.

How do you manage integration across Biostatistics, Programming, and Data Management?

With a coordinated operating model and governance structure that aligns teams early, reducing handoff friction and cross-functional rework.

How do you support ICH E9(R1) estimands and prospective analysis planning in practice?

By embedding estimand thinking into trial design, ensuring clear alignment between objectives, endpoints, and analysis strategy from protocol development onward.

What do you do to support data integrity and traceability expectations (ICH-aligned)?

We provide end-to-end traceability from data capture through analysis using controlled processes, validated programming, and audit-ready documentation.

How do you support CDISC compliance and submission-ready outputs?

By applying standardized data models and validated programming workflows to deliver CDISC-compliant datasets and eSubmission-ready packages.

What does “near real-time” data visibility mean in practice for sponsor decision-making?

Near real-time means accelerated, transparent data flow that provides timely, actionable insights for oversight, enabling faster, better-informed clinical decisions.